DVAX - ダイナバックス・テクノロジ―ズ (Dynavax Technologies Corporation) ダイナバックス・テクノロジ―ズ



symbol DVAx
会社名 Dynavax Technologies Corp (ダイナバックス・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダイナバクス・テクノロジーズ(Dynavax Technologies Corporation)は臨床段階の免疫療法会社である。同社はトール様受容体(TLR)刺激を通じて身体の本能と適応免疫応答を活用することに集中する。同社の製品候補は複数の癌適応症、B型肝炎の予防ワクチン、および喘息疾患修正療法として開発される。同社の製品はHEPLISAV-B、AZD1419、SD-101、DV281、DV230FとDV1001を含む。HEPLISAV-Bは治験成人のB型肝炎ワクチンである。AZD1419は喘息の治療として開発される。SD-101は癌に対する免疫応答を誘発するように設計される治験用TLR9アゴニストである。DV281は原発性肺腫瘍および肺転移への集中送達のためのTLR9アゴニストである。DV230Fは肝腫瘍の治療に適応する。DV1001は複数悪性腫瘍のTLR7、8アゴニストを標的とする。DV230FとDV1001は開発の前臨床段階である。   ダイナバックス・テクノロジ―ズは米国の臨床検査段階のバイオ医薬品会社。感染症、炎症性疾、自己免疫疾患治療薬の研究、開発に従事。候補製剤にはB型肝炎ワクチン「ヘプリサブ」、自己免疫疾患治療用「DV1179」、喘息治療用「AZD1419」、癌免疫療法「SD-101」などがある。   Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
本社所在地 2929 Seventh Street Suite 100 Berkeley CA 94710-2753 USA
代表者氏名 Arnold L. Oronsky アーノルドエルオロスキー
代表者役職名 Independent Chairman of the Board
電話番号 +1 510-848-5100
設立年月日 35278
市場名 NASDAQ Small Cap
ipoyear 2004年
従業員数 170人
url www.dynavax.com
nasdaq_url https://www.nasdaq.com/symbol/dvax
EBITDA EBITDA(百万ドル) -115.44000
終値(lastsale) 11.07
時価総額(marketcap) 693154537.02
時価総額 時価総額(百万ドル) 700.66840
売上高 売上高(百万ドル) 1.49300
企業価値(EV) 企業価値(EV)(百万ドル) 584.39640
当期純利益 当期純利益(百万ドル) -127.95100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Dynavax Technologies Corporation revenues increased from $253K to $1.4M. Net loss increased 72% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $2.3M to $17.5M (expense).



   Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B  2020/06/10 13:30:00 Zacks Investment Research
Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.
   Thinking about buying stock in Laredo Petroleum, Moneygram International, Dynavax Technologies, Riot Blockchain, or Allied Esports Entertainment?  2020/06/02 13:31:00 PR Newswire
NEW YORK, June 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPI, MGI, DVAX, RIOT, and AESE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs  2020/06/02 11:45:45 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aileron Therapeutics Inc (NASDAQ: ALRN ) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cerus Corporation (NASDAQ: CERS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) Emergent Biosolutions Inc (NYSE: EBS ) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) Imara Inc (NASDAQ: IMRA ) Immunovant Inc (NASDAQ: IMVT ) Inari Medical Inc (NASDAQ: NARI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MEI Pharma Inc (NASDAQ: MEIP ) Novo Nordisk A/S (NYSE: NVO ) Protara Therapeutics Inc (NASDAQ: TARA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) Ocugen Inc (NASDAQ: OCGN ) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs.
   Dynavax Technologies Announces Proposed Public Offering of Common Stock  2020/05/21 20:01:00 GlobeNewswire
EMERYVILLE, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing…
   Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More  2020/05/20 17:18:00 Zacks Investment Research
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
   Is the Options Market Predicting a Spike in Dynavax (DVAX) Stock?  2019/12/03 13:30:00 Zacks Investment Research
Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.
   Dynavax Technologies (NASDAQ:DVAX) Downgraded to “Hold” at BidaskClub  2019/11/08 11:50:46 Modern Readers
Dynavax Technologies (NASDAQ:DVAX) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Friday, BidAskClub reports. DVAX has been the topic of a number of other research reports. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research […]
   Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release  2019/10/30 14:34:24 Zacks Investment Research
Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Dynavax Technologies Corporation (DVAX) Shares March Higher, Can It Continue?  2019/08/19 13:53:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Dynavax Technologies Corporation (DVAX).
   Dynavax Technologies (DVAX) Reports Q2 Loss, Tops Revenue Estimates  2019/08/07 22:45:08 Zacks Investment Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -4.76% and 4.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Dynavax to focus on vaccines; CEO retires; shares -7.9%  2019-05-23
Dynavax (NASDAQ: DVAX ) is 7.9% lower after hours on announcing a restructuring to focus on its vaccine business. More news on: Dynavax Technologies Corporation, Healthcare stocks news, Stocks on the move, Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ダイナバックス・テクノロジ―ズ DVAX Dynavax Technologies Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)